The European Medicines Agency is looking to simplify the way it approves biosimilars by removing the need for “extensive” ...

GUBamy, AbbVie-licensed amylin drug from Gubra, shows 7.8% weight loss in Phase 1 trial, vs 2% weight gain with placebo after ...

Prazer Therapeutics raises $20M Series B with JJDC's first South Korean investment; Carisma cuts to 6 staff; Cerevance's ...

Isomorphic Labs CEO Demis Hassabis discusses $600M funding round, plans for a US office, and expanding into ...

Zus Health, led by former athenahealth CEO Jonathan Bush, aims to create unified health records. Company has 60+ customers ...

Talkspace is using AI to make mini podcast episodes from patients’ therapy sessions. The “Talkcast” episodes are meant to be ...

Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal ...

When the transatlantic startup AIRNA launched in 2023, it was already years behind other companies that were trying to bring ...

Eli Lilly's RNA drug solbinsiran reduced ApoB protein levels by 14.3% in Phase 2 cholesterol trial, competing with ...

Sanofi hires former GSK development head Chris Corsico as global R&D head, replacing Dietmar Berger who left for Gilead. Move ...

The FDA overstepped its authority when it issued a rule last May to bring laboratory-developed tests under the agency’s ...

Vaxcyte’s stock price dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an ...